|Send to printer »|
GEN News Highlights : Sep 22, 2009
Oxford BioMedica and AGI Therapeutics Push On with Drugs That Failed Phase III Trials
Firms retain confidence in TroVax in various cancer settings and Rezular in GI-related indications.!--h2>
Oxford BioMedica and AGI Therapeutics separately confirmed plans to continue development of candidates that did not fare as well as expected in Phase III trials.
In July of this year Oxford BioMedica confirmed receipt of final comments from the FDA, following the agency’s review of the Phase III TRIST study and the company’s proposed clinical development outline for TroVAx. The agency supported its proposal to pursue clinical development of TroVax in metastatic disease including colorectal, ovarian, hormone refractory prostate cancer, and triple-negative breast cancer prior to further trials in renal cancer. The agency also noted that in these indications, there tends to be less evidence of abnormal levels of platelets and other hematological parameters that could potentially impact adversely on the immune response to TroVax.
© 2016 Genetic Engineering & Biotechnology News, All Rights Reserved